Trial Profile
An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regimen to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lamivudine/zidovudine; Nevirapine
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms TRANxITION
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Apr 2012 Results published in HIV Medicine.
- 23 Feb 2012 Actual number of patients changed from 443 to 445 as reported by ClinicalTrials.gov.
- 23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.